Literature DB >> 19908923

Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected.

Allan Wailoo1, Aki Tsuchiya, Christopher McCabe.   

Abstract

Current practice in economic evaluation is to assign equal social value to a unit of health improvement ('a QALY is a QALY is a QALY'). Alternative equity positions are typically considered separately from efficiency. One proposal seeks to integrate these two sets of societal concerns by attaching equity weights to QALYs. To date, research in pursuit of this goal has focussed on candidate equity criteria and methods for estimating such weights. It has implicitly been assumed that should legitimate, valid and reliable equity weights become available, it would be a straightforward task to incorporate them as a separate simple calculation after estimating cost per un-weighted QALY. This article suggests that, in many situations, these simple approaches to incorporating equity weights will not appropriately reflect the preferences on which the weights are based and that the appropriate incorporation of equity weights in cost-effectiveness analyses will be technically challenging. In addition to the technical challenges, there are a number of issues that arise in the movement from implicit to explicit consideration of equity. Whilst equity weights can, conceptually, be incorporated in economic evaluation, there are a number of challenges to be addressed before the results of such analyses can be considered robust and a fit basis for resource allocation decisions.

Mesh:

Year:  2009        PMID: 19908923     DOI: 10.2165/11314100-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  7 in total

Review 1.  Resource allocation, social values and the QALY: a review of the debate and empirical evidence.

Authors:  David L B Schwappach
Journal:  Health Expect       Date:  2002-09       Impact factor: 3.377

2.  QALYs and the equity-efficiency trade-off.

Authors:  A Wagstaff
Journal:  J Health Econ       Date:  1991-05       Impact factor: 3.883

Review 3.  How much will Herceptin really cost?

Authors:  Ann Barrett; Tom Roques; Matthew Small; Richard D Smith
Journal:  BMJ       Date:  2006-11-25

Review 4.  Intergenerational equity: an exploration of the 'fair innings' argument.

Authors:  A Williams
Journal:  Health Econ       Date:  1997 Mar-Apr       Impact factor: 3.046

Review 5.  Towards the equitably efficient and transparently decidable use of public funds in the deep blue millennium.

Authors:  J Dowie
Journal:  Health Econ       Date:  1998-03       Impact factor: 3.046

6.  Incorporating societal concerns for fairness in numerical valuations of health programmes.

Authors:  E Nord; J L Pinto; J Richardson; P Menzel; P Ubel
Journal:  Health Econ       Date:  1999-02       Impact factor: 3.046

Review 7.  QALY maximisation and people's preferences: a methodological review of the literature.

Authors:  Paul Dolan; Rebecca Shaw; Aki Tsuchiya; Alan Williams
Journal:  Health Econ       Date:  2005-02       Impact factor: 3.046

  7 in total
  17 in total

1.  Criteria for fairly allocating scarce health-care resources to genetic tests: which matter most?

Authors:  Wolf H Rogowski; Scott D Grosse; Jörg Schmidtke; Georg Marckmann
Journal:  Eur J Hum Genet       Date:  2013-08-07       Impact factor: 4.246

2.  Valuing health at the end of life: an empirical study of public preferences.

Authors:  Koonal K Shah; Aki Tsuchiya; Allan J Wailoo
Journal:  Eur J Health Econ       Date:  2013-05-09

3.  Cost-Value Analysis and the SAVE: A Work in Progress, But an Option for Localised Decision Making?

Authors:  Jonathan Karnon; Andrew Partington
Journal:  Pharmacoeconomics       Date:  2015-12       Impact factor: 4.981

4.  HTA - Algorithm or Process? Comment on "Expanded HTA: Enhancing Fairness and Legitimacy".

Authors:  Anthony J Culyer
Journal:  Int J Health Policy Manag       Date:  2016-08-01

5.  When is it too expensive? Cost-effectiveness thresholds and health care decision-making.

Authors:  Werner Brouwer; Pieter van Baal; Job van Exel; Matthijs Versteegh
Journal:  Eur J Health Econ       Date:  2019-03

Review 6.  Integrating social justice concerns into economic evaluation for healthcare and public health: A systematic review.

Authors:  Vadim Dukhanin; Alexandra Searle; Alice Zwerling; David W Dowdy; Holly A Taylor; Maria W Merritt
Journal:  Soc Sci Med       Date:  2017-12-14       Impact factor: 4.634

7.  Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review.

Authors:  Thomas Ward; Ruben E Mujica-Mota; Anne E Spencer; Antonieta Medina-Lara
Journal:  Pharmacoeconomics       Date:  2021-10-29       Impact factor: 4.981

8.  Economic Evaluation of Childhood Obesity Interventions: Reflections and Suggestions.

Authors:  Emma Frew
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

Review 9.  How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.

Authors:  Alessandra Blonda; Yvonne Denier; Isabelle Huys; Steven Simoens
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

Review 10.  Conceptualising 'Benefits Beyond Health' in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis.

Authors:  Lidia Engel; Stirling Bryan; David G T Whitehurst
Journal:  Pharmacoeconomics       Date:  2021-08-23       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.